Show simple item record

dc.contributor.authorZangarini, Men_US
dc.contributor.authorBerry, Pen_US
dc.contributor.authorSludden, Jen_US
dc.contributor.authorRaynaud, FIen_US
dc.contributor.authorBanerji, Uen_US
dc.contributor.authorJones, Pen_US
dc.contributor.authorEdwards, Den_US
dc.contributor.authorVeal, GJen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2019-06-27T11:03:40Z
dc.date.issued2017-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28692309en_US
dc.identifier.citationBioanalysis, 2017, 9 (13), pp. 1001 - 1010en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3278
dc.identifier.eissn1757-6199en_US
dc.identifier.doi10.4155/bio-2017-0043en_US
dc.description.abstractAIM: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. METHODS & RESULTS: Sample preparation involved protein precipitation with acetonitrile following addition of 13C15N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. CONCLUSION: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.en_US
dc.format.extent1001 - 1010en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.subjectCCT245737en_US
dc.subjectCHK1en_US
dc.subjectLC–MS/MSen_US
dc.subjectSRA737en_US
dc.subjectcanceren_US
dc.subjectpharmacokineticsen_US
dc.subjectvalidation studyen_US
dc.subjectBlood Chemical Analysisen_US
dc.subjectCheckpoint Kinase 1en_US
dc.subjectChromatography, High Pressure Liquiden_US
dc.subjectHeterocyclic Compounds, 4 or More Ringsen_US
dc.subjectHumansen_US
dc.subjectLimit of Detectionen_US
dc.subjectLinear Modelsen_US
dc.subjectProtein Kinase Inhibitorsen_US
dc.subjectTandem Mass Spectrometryen_US
dc.titleDevelopment and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.en_US
dc.typeJournal Article
dcterms.dateAccepted2016-04-02en_US
rioxxterms.versionofrecord10.4155/bio-2017-0043en_US
rioxxterms.licenseref.urien_US
rioxxterms.licenseref.startdate2017-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBioanalysisen_US
pubs.issue13en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.publication-statusPublisheden_US
pubs.volume9en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)en_US
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
dc.contributor.icrauthorBanerji, Udaien_US
dc.contributor.icrauthorRaynaud, Florenceen_US
dc.contributor.icrauthorTurner, Lydiaen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record